Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q4 FY2021 Earnings Presentation
32 slides from Dishman Carbogen Amcis's earnings presentation, May 12, 2021
Slide 1: Exchange filing cover letter: investor presentation on audited results
dish man 12th May, 2021 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Sandra (E), Mumbai - 400 051. Ref.: Scrip
Slide 2: Quarter ended March 31st, 2021
Quarter ended March 31st, 2021 May 2021
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 17,137 16,948 4,976 4,534 4,453 2,994 26.8% 24.3% 2,538 26.3% 2,744 26.5% 14.3% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
ishman Carbogen Amcis QUARTER
Slide 8: Impact due to EDQM Observations and COVID-19
Impact due to EDQM Observations and COVID-19 Cautionary Statement The business was impacted due to European Directorate for the Quality of Medicines & HealthCare (EDQM) issues at the Bavla site for the company’s product Dihydrotachysterol and due to Covid impact on the overall economy. As such, the
Slide 9: Q4 FY21 Result Highlights
Q4 FY21 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,121 5,293 1,070 884 20.9% 16.7% Q4FY20 Q4FY21 Q4FY20 Q4FY21 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 11.1% 5.8 570 5.8% 942 4.9 776 306 Q4FY20 Q4FY21 Q4FY20 Q4FY21 *EBITDA excluding other income @
Slide 10: FY21 Result Highlights
FY21 RESULT HIGHLIGHTS Net REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 20,436 19,120 4,669 3,024 22.8% 15.8% FY20 FY21 FY20 FY21 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS 2,641 3,925 12.9% 2,779 778 25.0 4.1% 17.7 FY20 FY21 FY20 FY21 *EBITDA excluding other income and excluding
Slide 11: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q4 FY21 Q4 FY20 YoY % FY21 FY20 YoY % Income from Operations (Net) 5,293.2 5,121.1 3.4% 19,120.3 20,436.0 -6.4% COGS 1,663.9 1,361.8 22.2% 4,681.50 4,587.20 2.1% Employee Expenses 2,197.7 2,011.0 9.3% 8,729.1 7,622.7 14.5% Other Expenses 548.0 678.3 -19.
Slide 12: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Particulars (₹ mn) Mar-21 Mar-20 Particulars (₹ mn) Mar-21 Mar-20 Equity Share Capital 313.6 313.8 Property, plant and equipment 16,990.1 17,118.5 Other Equity 56,674.6 56,836.8 Capital Work in Progress 4,246.4 2,023.4 Right to use Lease Assets 3,178.1 1,787.7 Total - Shar
Slide 13: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q4 FY21 Q4 FY20 YoY % FY21 FY20 YoY % CRAMS (% of total) 73.1% 77.0% 74.9% 77.3% CRAMS - India 226.5 1,009.7 -77.6% 533.9 4,026.6 -86.7% CRAMS - Switzerland, France & China 3,425.4 2,783.2 23.1% 12,804.2 10,815.3 18.4% CRAMS - UK 2
Slide 14: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue – Q4 FY21 Total Operating Revenue – FY21 CRAMS – 73.1% Marketable Molecules – 26.9% CRAMS – 74.9% Marketable Molecules – 25.1% 5.9% 3.7% 5.6% 6.9% 45.3% 48.9% 51.1% 54.7% 88.5% 89.4% CRAMS - India CRAMS - India CRAMS - Switzerland, France & China
Slide 15: Segment-wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q4 FY21 Q4 FY20 FY21 FY20 CRAMS CRAMS- India - 48.5% - 45.8% CRAMS – Switzerland, France & China 18.6% 11.9% 19.0% 18.1% CRAMS - UK 21.6% 14.4% 19.5% 16.4% Marketable Molecules Carbogen Amcis BV 26.0% 26.9% 32.2% 31.6% Others 19.1% 10.2% 16.3% 10.6% *inc
Slide 16: Q4 & FY21 Result Highlights
Q4 & FY21 RESULT HIGHLIGHTS Net Revenue at Rs 5,293.2 mn in Q4 FY21 up by 3.4% YoY CRAMS revenue declined by 1.9% YoY primarily due to : CRAMS India revenue decreased by 77.6% due to EDQM observations but on account of certain successful customer audits and production of certain complex intermediate
Slide 17: Business Update – CRAMS NCE
BUSINESS UPDATE – CRAMS NCE Successfully reached agreement with a Japanese Client to commercially manufacture a novel oncology drug linker in a new facility co-funded with the Client and CGAM. Concluded a commercial supply agreement to manufacture a Hypoparathyroid drug for one of our Clients, a com
Slide 18: Business Update – Vitamin D
BUSINESS UPDATE – VITAMIN D VITAMIN D Our development teams continue their progress on 3 new projects in the synthetic cholesterol, and vitamin D2 areas that we are prioritizing across both India and Netherlands R&D teams. The R&D team in Netherlands has been strengthened to ensure timely throughput
Slide 19: Business Update – India
BUSINESS UPDATE – INDIA Completed manufacturing of a complex intermediate for a Swiss based customer. Completed the supply of an intermediate to CGAM for a commercial product for a European client. Completed several virtual client audits during Q4 FY 2021. Successfully completed the transfer of an i
Slide 20: Company Overview
ishman Carbogen Amcis COMPANY
Slide 21: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 22: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 23: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 24: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 25: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES Focus is on supporting the development process from bench to market Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 26: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 27: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY21 FY21 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 26
Slide 28: Industry Overview
ishman Carbogen Amcis INDUSTRY
Slide 29: Top 10 Therapy Areas (US$ bn) - 2019
2019 Global Sales by Therapy Areas Specialty areas dominate sales and growth driven by developed markets 0 20 40 60 80 100 120 140 160 Oncologics 44% 22% 8% 11% 15% $146 bn $97 bn Top 10 Therapy Areas (US$ bn) - 2019 11% Antidiabetics 66% 8% 5% 10% 11% $87 bn 2% Autoimmune Diseases 69% 14% 4% $47 bn
Slide 30: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Developed countries account for >80% of specialty market Specialty: Region Market Share 2019 Region Contribution to Global Growth 81% of all specialty sales from 7 countries 2014-19 2014-19 Absolute growth contribution in LCUS$ Market Specialty 12% 13% 13% US 6% 5% 2
Slide 31: Pharmerging Markets - Oncology Leads Growth
PHARMERGING MARKETS - ONCOLOGY LEADS GROWTH Pharmerging Top 10 therapy areas, value and volume growth 32% 17% Value PPG (%) 14%13% 13%12% 11% 10% 10% 9% 9% 8% 8% 8% 9% 7% 7% 5% 5% 2% 3% 4% 12% 11% 10% 9% 8% Volume PPG (%) 5% 6% 6% 3% 3% 3% 4% 4% 4% 4% 4% 4% 0% 0% 1% -2% -1% Pharmerging Antibacterial
Slide 32: Thank you!
Dishman Dishman Carbogen Amcis Limited CARBOGEN AMCIS AG Dishman Corporate House Hauptstrasse 171 Ambli Bopal Road CH-4416 Bubendorf Ahmedabad 380 058 Switzerland www.imdcal.com www.carbogen-amcis.com Thank you! FOR FURTHER QUERIES Mr. Binay Sarda Mr. Harshil Dalal Christensen IR Group CFO P: +91 22
Dishman Carbogen Amcis — Q4 FY2021 Earnings Presentation on 6ix